Cytotoxic, anti-proliferative and apoptotic effects of noscapine on human estrogen receptor positive (MCF-7) and negative (MDA-MB-231) breast cancer cell lines


Creative Commons License

Kocak C., Kocak F., Ozturk B., Tekin G., Vatansev H.

Bratislava Medical Journal, vol.121, no.1, pp.43-50, 2020 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 121 Issue: 1
  • Publication Date: 2020
  • Doi Number: 10.4149/bll_2020_007
  • Journal Name: Bratislava Medical Journal
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE
  • Page Numbers: pp.43-50
  • Keywords: Breast neoplasms, Docetaxel, Immunohistochemistry, MCF-7 cells, Noscapine, Tamoxifen
  • Uşak University Affiliated: Yes

Abstract

AIM: Noscapine, a naturally occurring alkaloid obtained from opium poppy, is a microtubule-targeting agent. This study is aimed to investigate the effects of noscapine on human breast cancer cell lines by comparing them with those of tamoxifen and docetaxel. METHODS: MCF-7 and MDA MB-23 cell lines were used to observe the effects of docetaxel, tamoxifen, and noscapine on cell proliferation. For each drug, cell blocks were prepared from cultured cells treated with IC50 dose of each drug and these were examined histologically. The expressions of Ki-67, Bcl-2, BAX, and cyclin-D1 were assessed immunohistochemically. RESULTS: Although noscapine showed cytotoxic effects on both cell lines in a time and dose dependent manner, MDA-MB-231 cells were more susceptible to its effects. Noscapine inhibited MCF-7 and MDAMB-231 cells proliferation in vitro with IC50 value of 29 μM and 69 μM, respectively, which was comparable with IC50 of tamoxifen (40 μM and 50 μM) and docetaxel (43 nM and 32 nM). Noscapine showed antiproliferative effects by decreasing Ki-67, cyclin-D1 and apoptotic effects by increasing BAX/Bcl-2 ratio in both breast cancer cells. Its effect was comparable with tamoxifen and docetaxel. CONCLUSION: Noscapine may be a good chemotherapeutic agent for the treatment of breast cancer, especially in estrogen receptor-negative breast cancer (Tab. 2, Fig. 7, Ref. 40). Text in PDF www.elis.sk.